Javascript must be enabled to continue!
Timing of device reimplantation and reinfection rates following cardiac implantable electronic device infection: a systematic review and meta-analysis
View through CrossRef
ObjectivesInitial management of cardiac implantable electronic device (CIED) infection requires removal of the infected CIED system and treatment with systemic antibiotics. However, the optimal timing to device reimplantation is unknown. The aim of this study was to quantify the incidence of reinfection after initial management of CIED infection, and to assess the effect of timing to reimplantation on reinfection rates.DesignSystematic review and meta-analysis.InterventionsA systematic review and meta-analysis was performed of studies published up to February 2018. Inclusion criteria were: (a) documented CIED infection, (b) studies that reported the timing to device reimplantation and (c) studies that reported the proportion of participants with device reinfection. A meta-analysis of proportions using a random effects model was performed to estimate the pooled device reinfection rate.Primary and secondary outcome measuresThe primary outcome measure was the rate of CIED reinfection. The secondary outcome was all-cause mortality.ResultsOf the 280 screened studies, 8 met inclusion criteria with an average of 96 participants per study (range 15–220 participants). The pooled incidence rate of device reinfection was 0.45% (95% CI, 0.02% to 1.23%) per person year. A longer time to device reimplantation >72 hours was associated with a trend towards higher rates of reinfection (unadjusted incident rate ratio 4.8; 95% CI 0.9 to 24.3, p=0.06); however, the meta-regression analysis was unable to adjust for important clinical covariates. There did not appear to be a difference in reinfection rates when time to reimplantation was stratified at 1 week. Heterogeneity was moderate (I2=61%).ConclusionsThe incident rate of reinfection following initial management of CIED infection is not insignificant. Time to reimplantation may affect subsequent rates of device reinfection. Our findings are considered exploratory and significant heterogeneity limits interpretation.PROSERO registration numberCRD4201810960.
Title: Timing of device reimplantation and reinfection rates following cardiac implantable electronic device infection: a systematic review and meta-analysis
Description:
ObjectivesInitial management of cardiac implantable electronic device (CIED) infection requires removal of the infected CIED system and treatment with systemic antibiotics.
However, the optimal timing to device reimplantation is unknown.
The aim of this study was to quantify the incidence of reinfection after initial management of CIED infection, and to assess the effect of timing to reimplantation on reinfection rates.
DesignSystematic review and meta-analysis.
InterventionsA systematic review and meta-analysis was performed of studies published up to February 2018.
Inclusion criteria were: (a) documented CIED infection, (b) studies that reported the timing to device reimplantation and (c) studies that reported the proportion of participants with device reinfection.
A meta-analysis of proportions using a random effects model was performed to estimate the pooled device reinfection rate.
Primary and secondary outcome measuresThe primary outcome measure was the rate of CIED reinfection.
The secondary outcome was all-cause mortality.
ResultsOf the 280 screened studies, 8 met inclusion criteria with an average of 96 participants per study (range 15–220 participants).
The pooled incidence rate of device reinfection was 0.
45% (95% CI, 0.
02% to 1.
23%) per person year.
A longer time to device reimplantation >72 hours was associated with a trend towards higher rates of reinfection (unadjusted incident rate ratio 4.
8; 95% CI 0.
9 to 24.
3, p=0.
06); however, the meta-regression analysis was unable to adjust for important clinical covariates.
There did not appear to be a difference in reinfection rates when time to reimplantation was stratified at 1 week.
Heterogeneity was moderate (I2=61%).
ConclusionsThe incident rate of reinfection following initial management of CIED infection is not insignificant.
Time to reimplantation may affect subsequent rates of device reinfection.
Our findings are considered exploratory and significant heterogeneity limits interpretation.
PROSERO registration numberCRD4201810960.
Related Results
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Abstract
The Physical Activity Guidelines for Americans (Guidelines) advises older adults to be as active as possible. Yet, despite the well documented benefits of physical a...
Urrets-Zavalia syndrome following implantable collamer lens (ICL) implantation: a case report and review of the literature
Urrets-Zavalia syndrome following implantable collamer lens (ICL) implantation: a case report and review of the literature
Abstract
Background
Urrets-Zavalia syndrome is a condition that arises after eye surgery, often linked to increased intraocular pressure followin...
Recurrence Possibility of COVID-19 in India
Recurrence Possibility of COVID-19 in India
Although nationwide lockdown was imposed in India amid COVID-19 outbreak since March 24, 2020, the COVID-19 infection is increasing day-by-day. India became world’s second most aff...
Outcomes of SARS-CoV-2 Reinfection
Outcomes of SARS-CoV-2 Reinfection
Abstract
First infection with SARS-CoV-2 is associated with increased risk of acute and post-acute death and sequelae in the pulmonary and extrapulmonary organ systems. How...
COVID-19 reinfection in Afghanistan: A descriptive analysis of data from DHIS2, 2022
COVID-19 reinfection in Afghanistan: A descriptive analysis of data from DHIS2, 2022
Background: Despite millions of COVID-19 infections worldwide since the beginning of the pandemic, relatively few confirmed cases of COVID-19 reinfection have been reported. In Afg...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
COVID-19 reinfection
COVID-19 reinfection
INTRODUCTION:
There are limited direct data on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) long-term immune responses and reinfection. This study aimed...
Prevalence and Reinfection Rates of Schistosoma mansoni and Praziquantel Efficacy against the Parasite among Primary School Children in Sanja Town, Northwest Ethiopia
Prevalence and Reinfection Rates of Schistosoma mansoni and Praziquantel Efficacy against the Parasite among Primary School Children in Sanja Town, Northwest Ethiopia
Background. Schistosomiasis is among the most widespread chronic infections in the world. The magnitude of the infection may show variations across different areas with respect to ...

